Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

Alternate Symbol(s):  OPSSF

OpSens Inc. is engaged in physiological measurements such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and in transcatheter aortic valve replacement (TAVR) in the structural heart market. The Company supplies an optical-based pressure guidewire (OptoWire), a guidewire used in the TAVR procedure (SavvyWire) and a wide range of miniature optical sensors to measure pressure and temperature to be used in a wide range of applications that can be integrated into other medical devices.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:Only a Matter of Time

Predators must be looking at Opsens's expansion all around the globe . Why not Australia soon !  rate and reply

Only a Matter of Time

Before Savvywire is used throughout the world. Put this one away, relax and come back in a couple of years with a big smile on your face. All IMHO of course. GLTA The launch in New Zealand more

Anfield Commissions Precision Systems Engineering to Develop Reactivation Plan for Shootaring Canyon Mill

The Company is pleased to announce that it has commissioned Precision Systems Engineering, a Utah-based engineering firm, to complete a reactivation proposal for the Shootaring Canyon Mill - one of only three licensed uranium mills in the US. The proposal, expected to be completed in Q2/23, will include a detailed study of the existing facility and uranium circuit, along with a preliminary more


QUEBEC CITY, Nov. 29, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that Dr. Sanjeevan Pasupati, Director of article.
@ the Bell: Unrest over COVID sanctions drags markets lower
After a few solid trading sessions, the TSX slid back into negative territory on Monday. Tech and industrial shares moved higher. read article.

This morning's La Presse _ Richard Dufour

Positive sentiment in spite of tweak in rating from Raymond James (my comment). Opsens fait toujours l’unanimit sur Bay Street, mais un analyste a ajust sa recommandation mardi aprs que more
@ the Bell: TSX logs best weekly performance since June
For the fourth straight session, the TSX closed higher for its best weekly gain since early June. read article.


Bargain basement price this morning. GLTA 09:18 AM EST, 11/25/2022 (MT Newswires) -- Stifel GMP on Friday reiterated its buy rating on the shares of Opsens (OPS.TO) and its C$3.75 price more

RE:Hang on from. Raymond James see Opsens trimmed at $ 5,00

Still holding but a smaller position . Still believe a buyout is our best option to maximize our products . Glta  rate and reply

Thematica Insights Report and Investor Guide

Thematica Report: Investing in undervalued stocks

The Market Herald launches Thematica's latest report: Unlocking the Advantages of Undervalued Stocks. Download it today!

RE:RE:Paradigm Capital...

Keep an eye out fr Board additions. These will be the people that smooth out stuff before takeover by a big company.  rate and reply

RE:Paradigm Capital...

Maybe sharing the link will be better... OpSens is a takeout target, says Paradigm Capital - Cantech Letter  rate and reply

Paradigm Capital...

OpSens is a takeout target, says Paradigm Capital Paradigm Capital analyst Scott McAuley still likes the look of Canadian medical device maker OpSens more
Buzz on the Bullboards: A briefing of the hottest & latest trends
Canada’s main stock index posted a solid rebound this week as energy stocks climbed along with the price of oil. Gains were capped by declines seen in the health care, and telecom sectors. read article.

Excellent coverage

In my humble opinion, the European market potential is currently being somewhat ignored.  Once that part of the world starts moving, we should see interesting things. GLTA  rate and reply


Their upside scenario target also remains at $5.00. GLTA November 22, 2022 Opsens Inc. FQ4/22: Revenues slightly below estimates; Positive early feedback more

Hang on from. Raymond James see Opsens trimmed at $ 5,00

Investors have to be patient ! Despite continuing to have “strong conviction” on the potential for its SavvyWire product as it continues to gain traction on both sides of the border, more

RE:RE:If I understand well...

Follow where the money went . Operating expenses for FY 2022 were $28.8 million compared with $19.6 million for FY 2021. The increase in operating expenses is primarily due to increased more

RE:If I understand well...

Good to see a voice of reason. We may close the day in the green depending on how well the conference call goes. GLTA  rate and reply

If I understand well...

... The increased loss is primarily due to higher operating expenses to drive growth in coronary products and preparation of the large-scale launch of SavvyWire for TAVR (Transcatheter more

RE:RE:Q4 2022 revenues lower than Q3 2022

When people like this show up (with a total of 4 posts on SH), you know it's time to buy. GLTA  rate and reply

Opsens parmi les 500 meilleures entreprises technologiques

La croissance exponentielle c'est maintenant que a se passe.Ils signent des contrats d'approvisionnement avec de nouveaux hopitaux de faon hebdomadaire. more

RE:Q4 2022 revenues lower than Q3 2022

hopeless in short term! Expected to go south to 1.8  rate and reply

Globe & Mail

Aside from tax losses, it doesn't make much sense to sell at this price. They've completed the painful part and now we will hopefully reap the benefits once we get the full scale launch more

Q4 2022 revenues lower than Q3 2022

Just to say this will  be a long and painfull journey ! At on point Opsens had a17% Y2021 /Y2020 and  now ''zero'' growth ! Very disapointing FR  Hopefully OPS more